Treatment outcomes and comparative survival analysis of intraductal carcinoma of the prostate
International Urology and Nephrology · 2025
DOI: 10.1007/s11255-025-04485-3 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift International Urology and Nephrology, 2025. Verfasst von Taylor Stamey und 6 weiteren Autor:innen. Beteiligte Einrichtung: Brody School of Medicine (BSOM), East Carolina University (ECU), 600 Moye Blvd, Greenville, NC, 27834, USA. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Carcinoma, Intraductal, Noninfiltrating. Die Arbeit nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: East Carolina University.
Abstract (Originalsprache)
Purpose
Intraductal carcinoma of the prostate is a rare subset of prostate cancer, for which no consensus treatment guidelines exist. We seek to investigate treatment and survival outcomes for IDC-P in the context of current NCCN guidelines.
Methods
The Surveillance, Epidemiology, and End Results (SEER) database was queried to identify patients with intraductal carcinoma of the prostate diagnosed between 2000 and 2020. Cox regression analysis and log-rank comparisons of both overall and cause-specific survival over 5- and 10-year timeframes were conducted.
Results
945 patients were identified. Cox regression analysis demonstrated treatment with unimodal surgery (hazard ratio (HR) = 3.70, p = 0.005) was associated with decreased 10-year cause-specific survival, while unimodal treatment with radiotherapy was associated with decreased 5- and 10-year overall survival (HR = 2.14, p = 0.025; HR = 2.16, p = 0.005, respectively). Univariate survival subanalysis of treatment regimens demonstrated decreased 5-year cause-specific ( p = 0.004) and overall ( p = 0.019) survival among patients that received only radiotherapy as treatment. Radical prostatectomy alone was non-inferior to radical prostatectomy with adjuvant radiotherapy in the context of 10-year overall survival (90% vs 80%; p = 0.58).
Conclusion
Differences in both 5- and 10-year overall survival and cause-specific survival were present among patients diagnosed with IDC-P. Treatment with unimodal radiotherapy among patients with IDC-P was associated with decreased survival compared to treatment with radical prostatectomy ± adjuvant radiotherapy, while radical prostatectomy alone was non-inferior to radical prostatectomy with adjuvant radiotherapy. Further research into the risk stratification and optimal treatment of these patients is warranted.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Brody School of Medicine (BSOM), East Carolina University (ECU), 600 Moye Blvd, Greenville, NC, 27834, USA.
- Department of Radiation Oncology, ECU, Greenville, NC, USA.
- Department of Pathology & Laboratory Medicine, ECU, Greenville, NC, USA.
- Division of Hematology/Oncology, Department of Internal Medicine, ECU, Greenville, NC, USA.
- Brody School of Medicine (BSOM), East Carolina University (ECU), 600 Moye Blvd, Greenville, NC, 27834, USA. larkinsm20@students.ecu.edu.
- Department of Emergency Medicine, Boonshoft School of Medicine at Wright State University, 2555 University Blvd, Fairborn, OH, USA. larkinsm20@students.ecu.edu.
Förderung
- East Carolina University
Zitieren
APA
Stamey, T., Armel, K., Ju, A. W., Chen, S., Navaid, M., Bhatt, A., & Larkins, M. C. (2025). Treatment outcomes and comparative survival analysis of intraductal carcinoma of the prostate. International Urology and Nephrology. https://doi.org/10.1007/s11255-025-04485-3
Vancouver
Stamey T, Armel K, Ju AW, Chen S, Navaid M, Bhatt A, et al. Treatment outcomes and comparative survival analysis of intraductal carcinoma of the prostate. International Urology and Nephrology. 2025. doi:10.1007/s11255-025-04485-3
BibTeX
@article{Stamey2025,
author = {Stamey, Taylor and Armel, Kristen and Ju, Andrew W and Chen, Shoujun and Navaid, Musharraf and Bhatt, Arjun and Larkins, Michael C},
title = {Treatment outcomes and comparative survival analysis of intraductal carcinoma of the prostate},
journal = {International Urology and Nephrology},
year = {2025},
doi = {10.1007/s11255-025-04485-3}
}
EUVIMED